Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13851512 | 0.87 | ALDH1A1 (0.50) | ACHESMN1; SMN2NPC1RAB9ATSHR | |
| SCHEMBL84195 | 0.86 | KMT2A (0.44) | NPC1RAB9ATSHRALDH1A1L3MBTL1 | |
| SCHEMBL987913 | 0.86 | KMT2A (0.44) | NPC1RAB9ATSHRALDH1A1L3MBTL1 | |
| SCHEMBL10315708 | 0.86 | KMT2A (0.44) | NPC1RAB9ATSHRALDH1A1L3MBTL1 | |
| SCHEMBL25970364 | 0.83 | OPRK1 (0.49) | ACHESMN1; SMN2NPC1RAB9ATSHR | |
| SCHEMBL7279699 | 0.79 | ATM (0.54) | NPC1RAB9AALDH1A1L3MBTL1MEN1 | |
| SCHEMBL1004393 | 0.78 | L3MBTL1 (0.48) | ACHESMN1; SMN2NPC1RAB9ATSHR | |
| SCHEMBL1004392 | 0.78 | L3MBTL1 (0.48) | ACHESMN1; SMN2NPC1RAB9ATSHR | |
| SCHEMBL1004394 | 0.78 | L3MBTL1 (0.48) | ACHESMN1; SMN2NPC1RAB9ATSHR | |
| SCHEMBL25970360 | 0.77 | ALDH1A1 (0.44) | ACHESMN1; SMN2NPC1RAB9ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9023860-B2 | Pro-drugs for controlled release of biologically active compounds | SIGNATURE THERAPEUTICS, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-20090137618-A1 | PRO-DRUGS FOR CONTROLLED RELEASE OF BIOLOGICALLY ACTIVE COMPOUNDS | 3I, LP | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137618-A1 | PRO-DRUGS FOR CONTROLLED RELEASE OF BIOLOGICALLY ACTIVE COMPOUNDS | CRH, FURIN, PEPD | ACHE 486/4885SMN1; SMN2 1019/4885NPC1 1492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.